TABLE 1.
Results of univariate analysis of various clinical and pathologic parameters of patients in both groups.
| Variables | Invasive carcinoma (n = 398) | HSIL (n = 2939) | Total (n = 3337) | p |
|---|---|---|---|---|
| Age (years) | ||||
| < 30 | 17 (4) | 242 (8) | 259 (8) | < 0.001 |
| 30–39 | 95 (24) | 1007 (34) | 1102 (33) | |
| 40–49 | 135 (34) | 913 (31) | 1048 (31) | |
| ≥ 50 | 151 (38) | 777 (26) | 928 (28) | |
| Menopause | ||||
| No | 281 (71) | 2377 (81) | 2658 (80) | < 0.001 |
| Yes | 117 (29) | 562 (19) | 679 (20) | |
| Parity (times) | ||||
| < 2 | 169 (42) | 1494 (51) | 1663 (50) | 0.002 |
| ≥ 2 | 229 (58) | 1445 (49) | 1674 (50) | |
| Gravidity (times) | ||||
| < 3 | 102 (26) | 956 (33) | 1058 (32) | 0.007 |
| ≥ 3 | 296 (74) | 1983 (67) | 2279 (68) | |
| Colporrhagia | ||||
| No | 307 (77) | 2525 (86) | 2832 (85) | < 0.001 |
| Yes | 91 (23) | 414 (14) | 505 (15) | |
| Vaginal_fluid | ||||
| No | 392 (98) | 2899 (99) | 3291 (99) | 0.995 |
| Yes | 6 (2) | 40 (1) | 46 (1) | |
| HPV type | ||||
| Type 16 and/or 18 | 200 (50) | 942 (32) | 2195 (66) | < 0.001 |
| Other HR‐HPV types or negative | 198 (50) | 1997 (68) | 1142 (34) | |
| Preoperative cytology | ||||
| Non‐HSIL | 131 (33) | 1876 (64) | 2007 (60) | < 0.001 |
| HSIL | 267 (67) | 1063 (36) | 1330 (40) | |
| Cervical biopsy | ||||
| CIN2 | 45 (11) | 1060 (36) | 1105 (33) | < 0.001 |
| CIN2‐3 | 160 (40) | 1159 (39) | 1319 (40) | |
| CIN3 | 193 (48) | 720 (24) | 913 (27) | |
| Gland involvement | ||||
| No | 230 (58) | 1913 (65) | 2143 (64) | 0.005 |
| Yes | 168 (42) | 1026 (35) | 1194 (36) | |
| Suspicious mesenchymal infiltration | ||||
| No | 319 (80) | 2784 (95) | 3103 (93) | < 0.001 |
| Yes | 79 (20) | 155 (5) | 234 (7) | |
| Endocervical curettage | ||||
| Non‐HSIL | 169 (42) | 2263 (77) | 2432 (73) | < 0.001 |
| HSIL | 229 (58) | 676 (23) | 905 (27) | |
Note: Cytology in the HSIL group includes ASC‐H, HSIL, AGC, and cervical cancer without a clear diagnosis.